Protalix BioTherapeutics, Inc. (NYSE:PLX) Director Aharon Schwartz Acquires 129,000 Shares

Key Points

• Director Aharon Schwartz of Protalix BioTherapeutics purchased 129,000 shares at an average price of $1.60, increasing his holdings by 74.14% to a total of 303,000 shares.
• Protalix BioTherapeutics has a market capitalization of approximately $130.56 million, with shares trading at $1.64, showing a recent increase despite having a 12-month low of $0.82.
• Institutional investors have significantly increased their stakes, with JPMorgan Chase & Co. raising its position by over 2000% in the second quarter.

Protalix BioTherapeutics, Inc. (NYSE:PLX - Get Free Report) Director Aharon Schwartz purchased 129,000 shares of Protalix BioTherapeutics stock in a transaction dated Tuesday, June 10th. The shares were purchased at an average price of $1.60 per share, for a total transaction of $206,400.00. Following the completion of the acquisition, the director owned 303,000 shares of the company's stock, valued at approximately $484,800. The trade was a 74.14% increase in their position. The acquisition was disclosed in a document filed with the SEC, which is accessible through this hyperlink.

Protalix BioTherapeutics Stock Performance

Shares of NYSE:PLX traded up $0.03 during midday trading on Tuesday, hitting $1.64. 546,976 shares of the stock were exchanged, compared to its average volume of 845,612. The stock has a market capitalization of $130.56 million, a price-to-earnings ratio of -12.62 and a beta of -0.21. The business's 50-day moving average price is $1.49 and its 200 day moving average price is $2.06. Protalix BioTherapeutics, Inc. has a 12 month low of $0.82 and a 12 month high of $3.10.

Protalix BioTherapeutics (NYSE:PLX - Get Free Report) last released its quarterly earnings results on Friday, May 9th. The company reported ($0.05) earnings per share for the quarter. Protalix BioTherapeutics had a negative return on equity of 30.89% and a negative net margin of 21.03%. As a group, sell-side analysts expect that Protalix BioTherapeutics, Inc. will post 0.01 EPS for the current year.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen cut Protalix BioTherapeutics from a "strong-buy" rating to a "buy" rating in a report on Monday, May 12th.

Hedge Funds Weigh In On Protalix BioTherapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. JPMorgan Chase & Co. lifted its stake in shares of Protalix BioTherapeutics by 2,065.8% in the second quarter. JPMorgan Chase & Co. now owns 34,545 shares of the company's stock worth $51,000 after acquiring an additional 32,950 shares during the period. Intech Investment Management LLC acquired a new position in shares of Protalix BioTherapeutics in the second quarter worth approximately $54,000. Police & Firemen s Retirement System of New Jersey acquired a new position in shares of Protalix BioTherapeutics in the second quarter worth approximately $27,000. Geode Capital Management LLC acquired a new position in shares of Protalix BioTherapeutics in the second quarter worth approximately $1,223,000. Finally, Cascade Financial Partners LLC acquired a new position in shares of Protalix BioTherapeutics in the second quarter worth approximately $25,000. 16.53% of the stock is owned by institutional investors and hedge funds.

Protalix BioTherapeutics Company Profile

Protalix BioTherapeutics, Inc, a biopharmaceutical company, engages in the development, production, and commercialization of recombinant therapeutic proteins based on its proprietary ProCellEx plant cell-based protein expression system in the United States, Australia, Canada, Israel, Brazil, Russia, Turkey, and internationally.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.